Results 11 to 20 of about 35,440 (172)

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib. [PDF]

PLoS ONE, 2015
Patients have responded well to the multi-targeted tyrosine kinase inhibitor (TKI) Sunitinib in the clinic. But the severe toxic side effects associated with Sunitinib limit its therapeutic index.
Qiang Huang, Changhua Zhou, Xiao Chen, Bing Dong, Siqi Chen, Ning Zhang, Yawei Liu, Anrong Li, Meicun Yao, Ji Miao, Qing Li, Zhong Wang   +11 more
doaj   +1 more source

Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). [PDF]

PLoS ONE, 2014
Hand-foot skin reaction is a most common multi-kinase inhibitor-related adverse event. This study aimed to examine whether the toxicity of sorafenib and sunitinib for human keratinocytes was associated with inhibiting signal transduction and activator of
Kazuhiro Yamamoto, Atsushi Mizumoto, Kohji Nishimura, Atsushi Uda, Akira Mukai, Kazuhiko Yamashita, Manabu Kume, Hiroo Makimoto, Toshinori Bito, Chikako Nishigori, Tsutomu Nakagawa, Takeshi Hirano, Midori Hirai   +12 more
doaj   +1 more source

Crizotinib and Sunitinib Induce Hepatotoxicity and Mitochondrial Apoptosis in L02 Cells via ROS and Nrf2 Signaling Pathway

Frontiers in Pharmacology, 2021
Considerable attention has been raised on crizotinib- and sunitinib-induced hepatotoxicity, but the underlying mechanisms need further examination. In addition, limited therapeutic strategies exist to reduce the liver damage caused by crizotinib and ...
Lin Guo, Hui Gong, Ting-Li Tang, Bi-Kui Zhang, Lei-Yi Zhang, Miao Yan   +5 more
doaj   +1 more source

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. [PDF]

PLoS ONE, 2015
Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is considered to be a standard treatment for metastatic ...
Noboru Shibasaki, Toshinari Yamasaki, Toru Kanno, Ryuichiro Arakaki, Hiromasa Sakamoto, Noriaki Utsunomiya, Takahiro Inoue, Tatsuaki Tsuruyama, Eijiro Nakamura, Osamu Ogawa, Tomomi Kamba   +10 more
doaj   +1 more source

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation

Frontiers in Oncology, 2021
BackgroundPercutaneous cryoablation (PCA) has emerged as an alternative to extirpative management of small renal masses in select patients. In recent years, the use of targeted therapies has become mainstream, while the role of PCA in treating primary ...
Cheng-Yuan Gu, Cheng-Yuan Gu, Jun-jie Wang, Jun-jie Wang, Hai-Liang Zhang, Hai-Liang Zhang, Guo-Hai Shi, Guo-Hai Shi, Ding-Wei Ye, Ding-Wei Ye   +9 more
doaj   +1 more source

Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib

Case Reports in Oncology, 2012
Sunitinib has been approved for the treatment of advanced and/or metastatic renal cell carcinoma (RCC). Information on the dosage adjustment of sunitinib for patients undergoing hemodialysis is limited.
Satoshi Noda, Susumu Kageyama, Teruhiko Tsuru, Shigehisa Kubota, Tetsuya Yoshida, Keisei Okamoto, Yusaku Okada, Shin-ya Morita, Tomohiro Terada   +8 more
doaj   +1 more source

Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer

Neoplasia: An International Journal for Oncology Research, 2022
Sunitinib is an effective treatment for patients with metastatic Renal Cell Carcinoma (mRCC) but ultimately resistance occurs. The aim of this study was to investigate sunitinib resistance in RCCs and to develop therapeutic combination strategies with ...
Jeannette C. Oosterwijk-Wakka, Mirjam C.A. de Weijert, Gerben M. Franssen, Dimitar R. Kolev, Ton A.F.J. de Haan, Otto C. Boerman, Peter F.A. Mulders, Egbert Oosterwijk   +7 more
doaj   +1 more source

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

BMC Cancer, 2022
Background Tyrosine kinase inhibitors (TKIs), such as sunitinib, are used for cancer treatment, but may also affect platelet count and function with possible hemostatic consequences.
Bibian M. E. Tullemans, Sanne L. N. Brouns, Frauke Swieringa, Siamack Sabrkhany, Franchette W. P. J. van den Berkmortel, Natascha A. J. B. Peters, Peter de Bruijn, Stijn L. W. Koolen, Johan W. M. Heemskerk, Maureen J. B. Aarts, Marijke J. E. Kuijpers   +10 more
doaj   +1 more source

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

Cell Reports, 2013
Preclinical studies have suggested that sunitinib accelerates metastases in animals, ascribing this to inhibition of the vascular endothelial growth factor receptor or the tumor’s adaptation.
Krastan B. Blagoev, Julia Wilkerson, Wilfred D. Stein, Robert J. Motzer, Susan E. Bates, A. Tito Fojo   +5 more
doaj   +1 more source

Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma

Frontiers in Oncology, 2020
Although sunitinib contributes to prolonging the progression-free survival of metastatic renal cell carcinoma significantly, the universal presence of resistance limits the initial response rate and restricts durable responses. The mechanisms involved in
Liping Shan, Wei Liu, Yunhong Zhan
doaj   +1 more source